A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
← catalyst calendarSponsored by Compass Therapeutics (industry) · CMPX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
49actual
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-12-08 | actual | When the study began enrolling |
| Primary completion | 2025-05-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-15 | actual | The whole study's end, after follow-up |
| First posted | 2022-08-24 | actual | When this record first appeared on the registry |
| Results posted | 2026-07-28 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic Colorectal Cancer
- Colon Cancer
- Rectal Cancer
Intervention
- Drug: CTX-009
Primary outcome
what the primary-completion date above is the date OFOverall Response Rate
measured From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-07-05 · 1.3 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-05-05 · 813 KB · SAP_001.pdf
Permalink · CMPX's whole pipeline · Catalyst calendar · Every registered study · What changed